Global Market for Mucormycosis is Expected to Grow at a CAGR of Approximately 7.3% during the forecast period, 2017-2023

Pune, India, February 9 2018 /MRFR Press Release/- Market Research Future has published a half-cooked research report on the global mucormycosis market

Market Highlights

Zygomycosis also known as mucormycosis is a rare infection caused by organisms that belong to a group of fungi called Mucoromycotina. These fungi are typically found in the soil and are associated with decaying organic matter, such as leaves, compost piles or rotten wood. The treatments for mucormycosis include the use of amphotericin B therapy. The therapy should be immediately administered due to the rapid spread and high mortality rate of the disease.

There are many types of antifungal treatments available in the market. However, many of them have different side effects and thus, there is a huge opportunity for the manufacturers to develop new drugs. Isavuconazole was recently approved by the FDA to treat invasive aspergillosis and invasive mucormycosis. Many drugs are not prescribed to pregnant women and children. Besides this, there are huge opportunities for the market in developing countries. Thus, the development of new drugs can be a huge opportunity for the growth of the market.

Regional Analysis

The global mucormycosis market consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas’ mucormycosis market accounted for the largest market share in 2016, which can be attributed to the presence of huge patient population, increasing prevalence of fungal diseases, and huge healthcare expenditure. Europe accounted for the second largest market which is followed by Asia Pacific. The U.S. and European biotechnology companies with less than USD 500 Million turnover invested about USD 41.3 Billion in the year 2015. The companies such as Gilead, Celgene, Amgen, and Biogen accounted for the majority of the share.

Asia Pacific is expected to be the fastest growing region in the mucormycosis market over the forecasted period. The annual prevalence of all-type of mycoses increased from 6.9% in 2009 to 7.4% in 2013. The prevalence of subcutaneous mycoses and generalized mycoses was very low i.e.8 cases per 100,000 persons.

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

Access Report Deatails @ https://www.marketresearchfuture.com/reports/mucormycosis-market-5440 

Segmentation

The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.

On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs are further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, flucytosine, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Key Players

Some of key the players in the global mucormycosis market are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com